8.62
+0.21
+(2.54%)
As of 8:10:36 AM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
847,250.00
556,382.00
1,598,951.00
197,581.00
22,388.00
Cost of Revenue
321,046.00
343,768.00
902,639.00
--
--
Gross Profit
526,204.00
212,614.00
696,312.00
197,581.00
22,388.00
Operating Expense
827,623.00
779,125.00
1,341,048.00
1,884,157.00
439,107.00
Operating Income
-301,419.00
-566,511.00
-644,736.00
-1,686,576.00
-416,719.00
Net Non Operating Interest Income Expense
-16,607.00
-14,416.00
-19,880.00
-21,127.00
-15,145.00
Other Income Expense
38,291.00
37,896.00
10,969.00
-6,833.00
13,605.00
Pretax Income
-279,735.00
-543,031.00
-653,647.00
-1,714,536.00
-418,259.00
Tax Provision
5,123.00
2,031.00
4,292.00
29,215.00
--
Net Income Common Stockholders
-284,858.00
-545,062.00
-657,939.00
-1,743,751.00
-418,259.00
Diluted NI Available to Com Stockholders
-284,858.00
-545,062.00
-657,939.00
-1,743,751.00
-418,259.00
Basic EPS
-2.18
-5.41
-8.42
-23.44
-7.27
Diluted EPS
-2.18
-5.41
-8.42
-23.44
-7.27
Basic Average Shares
143,098.00
100,768.00
78,183.00
74,400.00
57,554.00
Diluted Average Shares
143,098.00
100,768.00
78,183.00
74,400.00
57,554.00
Total Operating Income as Reported
-301,419.00
-566,511.00
-644,736.00
-1,686,576.00
-416,719.00
Total Expenses
1,148,669.00
1,122,893.00
2,243,687.00
1,884,157.00
439,107.00
Net Income from Continuing & Discontinued Operation
-284,858.00
-545,062.00
-657,939.00
-1,743,751.00
-418,259.00
Normalized Income
-284,858.00
-545,062.00
-657,939.00
-1,743,751.00
-418,259.00
Interest Expense
16,607.00
14,416.00
19,880.00
21,127.00
15,145.00
Net Interest Income
-16,607.00
-14,416.00
-19,880.00
-21,127.00
-15,145.00
EBIT
-263,128.00
-528,615.00
-633,767.00
-1,693,409.00
-403,114.00
EBITDA
-216,355.00
-487,390.00
-604,713.00
-1,680,748.00
-398,229.00
Reconciled Cost of Revenue
321,046.00
343,768.00
902,639.00
--
--
Reconciled Depreciation
46,773.00
41,225.00
29,054.00
12,661.00
4,885.00
Net Income from Continuing Operation Net Minority Interest
-284,858.00
-545,062.00
-657,939.00
-1,743,751.00
-418,259.00
Total Unusual Items Excluding Goodwill
--
--
--
1,364.00
1,014.00
Total Unusual Items
--
--
--
1,364.00
1,014.00
Normalized EBITDA
-216,355.00
-487,390.00
-604,713.00
-1,680,748.00
-398,229.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
--
12/31/2020 - 9/9/2009
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
GBY.F Sangamo Therapeutics, Inc.
1.1414
+9.10%
NMLSD Restart Life Sciences Corp.
0.0316
0.00%
MRES Institute of Biomedical Research Corp.
0.0171
+6.87%
TPIA Mycotopia Therapies, Inc.
0.0315
+18.87%
ENDV Endonovo Therapeutics, Inc.
0.0002
-33.33%
NFX.L Nuformix plc
0.0700
-6.67%
TYRA Tyra Biosciences, Inc.
14.37
-2.31%
MLYS Mineralys Therapeutics, Inc.
10.32
+0.44%
IDIA.SW Idorsia Ltd
0.7040
-1.61%
SANN.SW Santhera Pharmaceuticals Holding AG
17.12
+4.39%